Beaver W T, Wallenstein S L, Rogers A, Houde R W
J Pharmacol Exp Ther. 1978 Oct;207(1):92-100.
The relative analgesic potency of oral and intramuscular codeine was evaluated in a double-blind crossover comparison of graded single doses in patients with chronic pain due to cancer. When both duration and intensity of analgesia are considered (total effect), oral codeine was 6/10 as potent as the intramuscular form. This is a high oral/parenteral analgesic relative potency ratio compared with morphine, metopon and oxymorphone and correlates well with the results of recent studies which have determined the oral vs. intramuscular bioavailability of codeine in man. Oral and intramuscular oxycodone were also compared in a similar patient group. Like codeine, oxycodone retained at least 1/2 of its analgesic activity when administered orally. We hypothesize that the high oral/parenteral relative potency ratios of codeine and oxycodone relative to morphine and its congeners are not due to more efficient absorption after oral administration, but rather that methylation at position 3 in codeine and oxycodone protects these drugs from rapid first-pass metabolism.
在一项针对癌症所致慢性疼痛患者的分级单剂量双盲交叉比较中,评估了口服和肌肉注射可待因的相对镇痛效力。当同时考虑镇痛的持续时间和强度(总效应)时,口服可待因的效力为肌肉注射形式的6/10。与吗啡、美托酮和羟吗啡酮相比,这是一个较高的口服/胃肠外镇痛相对效力比,并且与近期确定人体中可待因口服与肌肉注射生物利用度的研究结果密切相关。在相似的患者组中还比较了口服和肌肉注射羟考酮。与可待因一样,羟考酮口服给药时保留了至少1/2的镇痛活性。我们推测,可待因和羟考酮相对于吗啡及其同系物的高口服/胃肠外相对效力比并非由于口服给药后吸收更有效,而是可待因和羟考酮3位的甲基化保护这些药物免于快速的首过代谢。